Circulating miRNA analysis with NGS

 
Sep 25, 2017 9:30 AM–10:30 AM (EDT)
Duration: 1hrs
Circulating RNA can serve as a powerful biomarker for patient stratification and assessment of overall health and prognosis. In this webinar, we will focus on using next-generation sequencing (NGS) for identification of miRNA and mRNAs from biofluids, including best practices for designing and executing a successful experiment.

While RNA is vulnerable to degradation in serum/plasma due to the abundance of RNases and other degrading enzymes, RNA (including mRNA and miRNA) is protected within exosomes and other types of vesicles. Enrichment of exosomes from biofluids provides a supply of RNA biomarkers that can be profiled by NGS and further verified using targeted sequencing or qPCR.

In this webinar, we will show you how QIAGEN’s QIAseq miRNA Library Kit, with is based on the use of Unique Molecular Index (UMI) technology, gives researchers several advantages compared to other small RNA sequencing kits. The QIAseq miRNA Library Kit delivers a gel-free workflow and requires as little as 1 ng of total RNA as input. Its proprietary chemistry minimizes ligation bias and increases the number of miRNA reads by actively blocking irrelevant, contaminating side products and RNAs. Other kits on the market may suggest a gel-free workflow and reduce ligation bias, but their protocols and methods often fall short on delivering these promises. With the inclusion of UMIs in the QIAseq miRNA Library Kit, you can be sure that you have sequenced deep enough to cover the entire library and PCR without sequencing bias and errors.

In addition, we will address workflows for exosome mRNA discovery using stranded RNA-seq and subsequent verification using targeted RNA-seq. QIAGEN’s exosome RNA discovery pipeline starts with a global view of the expressed RNA which is accurately identified using the QIAGEN Biomedical Workbench’s tunable algorithm and verified using QIAseq Targeted RNA Panels. These targeted panels employ UMIs to ensure accurate quantification and adequate sequencing depth for each sample you run.

Join the webinar to hear what the RNA experts have to say about the ‘next generation’ of sequencing-based workflows for biomarker detection and verification!

Dr. Sam Rulli

Samuel J. Rulli

Samuel Rulli is an R&D Scientist in qPCR applications at QIAGEN and has spent three years in the biotech industry as a qPCR specialist developing, evaluating, and teaching different qPCR technologies and applications. Dr. Rulli received his PhD in 2002 from Tulane University studying the gastric proton pump and did post-doctoral research at Johns Hopkins University and the National Cancer Institute in Frederick, MD. Trained as a molecular biologist, Dr. Rulli has worked on different assay detection technologies for gene expression and nucleic acid analysis.